Provention Bio, Inc. (PRVB)
(Delayed Data from NSDQ)
$3.98 USD
+0.18 (4.74%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[PRVB]
Reports for Purchase
Showing records 41 - 48 ( 48 total )
Industry: Medical - Biomedical and Genetics
At-Risk Trial Proves Teplizumab Delays Diabetes Onset; Rapid Pathway Possible; Reiterate Buy; Raising Target to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; PULSE Failure Does Not Impact Our Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Phase 2a PRINCE Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
PROTECT Pivotal Phase 3 Trial Starts Ahead of Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
2018 Financials Reported; Clinical Data Catalysts Ahead; Reiterate Buy and Raising Target to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Recent Industry Licensing Deal Adds Credence to Provention''s Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Multi-Strain Coxsackievirus B Vaccine Patent Allowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Intercepting Immune Disorders Ahead of the Curve; Initiating at Buy and $7.50 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R